Amolyt Pharma
Amolyt Pharma to Present Preliminary Phase 1 Data on AZP-3601 for Hypoparathyroidism and Additional Preclinical Data on AZP-3404 at ENDO 2021
Amolyt Pharma to Present Preliminary Phase 1 Data on AZP-3601 for Hypoparathyroidism and Additional Preclinical Data on AZP-3404 at ENDO 2021
Four abstracts accepted as poster presentations for the Endocrine Society’s Annual Meeting
LYON, France and NEWTON, Mass., March 16, 2021 (GLOBE NEWSWIRE) Amolyt Pharma, a global company specializing in developing therapeutic peptides for rare endocrine and metabolic diseases, today announced that it will be presenting four abstracts at the Endocrine Society’s Annual Meeting, ENDO 2021, being held virtually from March 20-23, 2021.
(0)
Four abstracts accepted as poster presentations for the Endocrine Society s Annual Meeting
LYON, France and NEWTON, Mass., March 16, 2021 (GLOBE NEWSWIRE) Amolyt Pharma, a global company specializing in developing therapeutic peptides for rare endocrine and metabolic diseases, today announced that it will be presenting four abstracts at the Endocrine Society s Annual Meeting, ENDO 2021, being held virtually from March 20-23, 2021.
Amolyt will present preliminary data from its Phase 1 clinical trial evaluating AZP-3601, a parathyroid hormone analog specifically designed for the treatment of hypoparathyroidism, in addition to two abstracts detailing a retrospective natural history study of chronic hypoparathyroidism. Amolyt will also present preclinical data for AZP-3404, a peptide with a new and unique mechanism of action on fat and glucose metabolism. Details of the abstracts are as follows: